Meeting
Abstract Number: 305
Hospital Medicine 2020, Virtual Competition
Background: In an effort to improve the design of future noninferiority studies, the endpoints for registrational trials of antimicrobials for the treatment of community-acquired bacterial pneumonia (CABP) were recently updated [1]. Lefamulin (LEF) is a first-in-class systemic pleuromutilin antibiotic newly approved for the treatment of adults with CABP [2]. The efficacy of LEF was demonstrated […]